ABSTRACT IL-1b is a "master" cytokine regulating a wide variety of physiologic and immunologic processes. The most frequently studied models for NLRP3 inflammasomemediated IL-1b production are the macrophages; however, depending on their microenvironment, they can develop into functionally different cells. Several protocols have been developed to model the diversity of these cells in vitro. Here, we report for the first time, to our knowledge, a comparative study about the dynamics and molecular mechanisms of NLRP3 inflammasome priming and activation in LPS-stimulated, human, monocytederived GM-or M-macrophages, differentiated in the presence of GM-CSF or M-CSF, respectively. Our results show that IL-1b production by LPS-stimulated M-macrophages is a rapid and short event that requires ATP supplementation and is attenuated, in part, by the presence of IL-10, which reduces Akt signaling. However, IL-1b production by GMmacrophages develops gradually, and these cells produce IL-1b, even in the absence of ATP supplementation, because of the constitutively active caspase-1 enzyme. We show that the membranebound ectonucleotidases have an important regulatory role on the IL-1b secretion in GM-macrophages. Furthermore, we provide evidence that adenosine treatment enhances LPS-primed IL-1b secretion by GM-macrophages, but not by M-macrophages. These results show that, because of the different activation status and expression levels of the NLRP3 inflammasome components, as well as the signaling activity of the pathways, the two subtypes of macrophages respond very differently to the same stimuli. For this reason, the molecular composition of the microenvironment that shapes macrophage development should be considered when research or therapeutic methods are planned to control IL-1b production.
Introduction
IL-1b is a master conductor cytokine that regulates not only acute or chronic inflammatory responses but also participates in processes such as wound healing, tissue regeneration, and the development of pain [1] [2] [3] . Because of its potent ability to induce several immunologic and physiologic functions, the secretion of the active form of the cytokine is under tight regulation, which is mediated by multiprotein complexes called inflammasomes. Depending on the sensory part of the complex, several types of inflammasomes have been described that are specialized to recognize different molecular patterns. One of the most studied inflammasome complexes is the NLRP3 inflammasome that contains multiple copies of NLRP3 sensors, ASC adaptors, and caspase-1 enzymes. It has been proposed that the activation of the NLRP3 inflammasome requires 2 distinct signals. The first, socalled priming signal is typically induced by TLRs that trigger the expression of pro-IL-1b and the components of the inflammasome (NLRP3) through several signal transduction pathways, such as those involving p38, ERK, and NF-kB [4] [5] [6] . The second signal leads to the assembly of the inflammasome complex, the activation of caspase-1, and the cleavage of the inactive pro-IL-1b to mature cytokines. The second signal may be triggered by a variety of molecules that function as pathogen-associated molecular patterns or danger-associated molecular patterns, such as extracellular ATP. ATP may be released from injured cells during inflammation and tissue damage, which is then recognized by P2X7R, inducing significant changes in the intracellular milieu, such as the efflux of K + , influx of Ca 2+ , and enhanced production of reactive oxygen species. The extracellular accumulation of ATP reflects the balance between ATP release by cells and ATP hydrolysis by ectonucleotidases [7, 8] .
One of the main sources of IL-1b is MFs; however, MFs are very plastic, and may be characterized by different morphologic and functional properties. The development and polarization of MFs is highly dependent on the specific microenvironment [9] [10] [11] .
Several protocols have been developed to model these systems and enable the study of MFs in in vitro conditions. In a murine model, MFs are purified from the peritoneum or from alveolar lavage, or differentiated from the bone marrow in the presence of M-CSF, whereas in a human model, MFs are differentiated from monocytes, and either M-CSF or GM-CSF provides the condition for development. A series of comparative analysis and genome-wide studies have shown that both cell types possess MFspecific markers. However, it was also shown that cells differentiated with M-CSF will result in MFs (M-MFs) that produce low amount of proinflammatory cytokines, such as IL-6, TNF-a, and IL-23 [12, 13] , and by producing high levels of IL-10, they mainly participate in the resolution of inflammation, wound healing, and tissue regeneration. On the other hand, MFs differentiated in the presence of GM-CSF develop into MFs (GM-MFs) that efficiently mediate and maintain inflammatory processes, through the production of specific cytokines, such as IL-1b [14, 15] .
In humans, most studies of NLRP3 inflammasome-mediated IL-1b production are performed on M-MFs. Although there are comparative studies regarding gene expressions and general immune functions of the two MFs subtypes, because of the special conditions required for NLRP3 inflammasome activation and the subsequent secretion of IL-1b, these studies do not provide enough information about the molecular mechanisms and details of the activation process.
In our study, we describe, for the first time to our knowledge, the different dynamics of the LPS-induced NLRP3 inflammasome-mediated IL-1b secretion in the two human MF subtypes. We show that, although both GM-and M-MFs are able to produce similar amounts of IL-1b in the presence of ATP or nigericin, they differ substantially in the dynamics of their secretion. IL-1b secretion by M-MFs is a rapid process because of the half-primed state of these cells provided by the M-CSF-induced constitutive phosphorylation of ERK signaling pathway. We also show that IL-1b secretion by M-MFs lasts for only a short time, in part because of the inhibitory effect of IL-10 that attenuates Akt signaling and subsequently downregulates the transcription of pro-IL-1b. We report that GM-MFs are able to produce a significant amount of IL-1b, even in the absence of ATP supplementation, and this cytokine secretion is not influenced directly by the released endogenous ATP. However, we show that inhibition of CD39 and CD73 ectonucleotidases significantly changes IL-1b release, and adenosine, one of the end products of the ectonucleotidase function, significantly enhances IL-1b production in GM-MFs but not in M-MFs. Finally, we provide evidence that the caspase-1 enzyme is constitutively active in GM-MFs, which perhaps explains the observed IL-1b secretion in the absence of ATP supplementation.
MATERIALS AND METHODS

Reagents
Ultrapure LPS from Escherichia coli was purchased from InvivoGen (San Diego, CA, USA). ATP, A740003 (selective P2X7 purinoceptor antagonist), ARL67156 (ecto-ATPase inhibitor), and apyrase (high activity), ZM241385 (A2a-specific antagonist), PSB1115 (A2b-specific antagonist), DPCPX (A1-specific antagonist), and VUF5574 (A3-specific antagonist) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Z-YVAD-FMK (caspase-1 inhibitor) was purchased from BioVision Technologies (Milpitas, CA, USA). Anti-human IL-10 was obtained from Thermo Fisher Scientific (San Diego, CA, USA), and recombinant human IL-10 was from PeproTech (Rocky Hill, NJ, USA).
Monocyte isolation and MF differentiation
Leukocyte-enriched buffy coats were obtained from healthy blood donors in accordance with the written approval of the Director of the National Blood Transfusion Service and the Regional and Institutional Ethics Committee of the University of Debrecen (Debrecen, Hungary). Informed consent of all participating subjects was obtained. Mononuclear cells were isolated by density-gradient centrifugation using Ficoll Paque PLUS (GE Healthcare Life Sciences, Little Chalfont, United Kingdom), and CD14 + monocytes were separated with anti-CD14-conjugated microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany 
Measurement of ATP
Medium collected from MFs was centrifuged, and the ATP content was determined from cell-free supernatants immediately after collection by ATPlite luminescence assay kit (PerkinElmer, Budapest, Hungary) according to the manufacturer's instructions. Luminescence was measured with a Wallac 1420 Victor2 fluorometer-luminometer (Wallac Oy, Turku, Finland).
ELISA
Supernatants collected from MFs were centrifuged and stored at 220°C until further use. IL-6, TNF-a, IL-10, and IL-8 were detected from the ATPuntreated samples, and IL-1b was measured from ATP-untreated and -treated samples by ELISA (BD Biosciences, San Diego, CA, USA) according to the manufacturer's instructions. Analysis was performed on a FlexStation 3 Microplate Reader (Molecular Devices, Sunnyvale, CA, USA). The minimum detectable doses were 0.8 pg/ml for IL-1b and IL-8, 2 pg/ml for IL-10 and TNF-a, and 2.2 pg/ml for IL-6. 
RNA preparation and RT-PCR
Measurement of caspase-1 activity
Caspase-1 activity in cell lysates was determined using the acetylated and AMCconjugated fluorometric peptide substrate Acetyl-Tyr-Glu-Val-Asp-7-amino-4-methyl-coumarin (AnaSpec, San Jose, CA, USA). Lysis of the cells was performed on ice for 30 min in 50 mM Tris-HCl, pH 7.5, containing 150 mM NaCl, 0.5 mM EDTA, 0.5% nonidet P-40, 1 mM PMSF, 1 mg/ml aprotinin, 0.5 mg/ml pepstatin, 1.25 mg/ml leupeptin, and 1 mM dithiothreitol. After centrifugation (10,000 g, 10 min at 4°C), 30 mg protein lysate supernatant was incubated in 100 ml lysis buffer with 40 mM substrate (final concentration) in microtiter plate wells at room temperature, and the increase in fluorescence from the release of AMC was detected at 460 nm, using 355 nm excitation wavelength in a Wallac 1420 Victor2 fluorometer-luminometer (Wallac Oy).
siRNA transfection
On d 3 of differentiation, supernatants were collected and cells were suspended in PBS, then washed once with OptiMEM (Invitrogen, Carlsbad, CA, USA). Cells were transfected with NLRP3-specific siRNA (s38591, s38592, s38593) or with siRNA for negative control (Ambion) using an electroporator (Gene Pulser Xcell; Bio-Rad). Finally, cells were plated in 24-well tissue culture plates (1 3 10 6 cells/ml). On d 5, MFs (M-MFs, GM-MFs) were stimulated with LPS (500 ng/ml).
Statistical analysis
Significant differences between mean values were evaluated using a Student's t test. Data are presented as means 6 SD.
RESULTS
LPS treatment of M-MFs and GM-MFs results in a different pattern of cytokine expression
The different functions of various MF subtypes are manifested in part by the production of a characteristic cytokine profile. To compare how stimulation affects cytokine production of M-MFs and GM-MFs, cells were treated with LPS for various time intervals, and cytokine production was determined using ELISA methods ( Fig. 1) . Figure 1 . GM-MFs produce predominantly proinflammatory cytokines.
(A) M-MFs and GM-MFs were primed with LPS (500 ng/ml) for the indicated times and TNF-a, IL-6, IL-8, and IL-10 cytokines were quantified from cell-free supernatants, n = 3. Means 6 SD values are provided for TNF-a and IL-8 (*P , 0.1, **P , 0.05), IL-6 (***P , 0.0001), and IL-10 (*P , 0.1, **P , 0.01). (B) MFs were treated with LPS and ATP (left panel; n = 6) or with LPS and nigericin (nig) (right panel; n = 3). IL-1b was then measured from the supernatants (*P , 0.05, **P , 0.001, ***P , 0.0001). (C) MFs (n = 6) and monocytes (n = 3) were treated with LPS in the absence of ATP supplementation, and IL-1b level was detected (*P , 0.05, **P , 0.005). ELISA methods were performed in triplicates.
We found that both MF subtypes produced detectable amount of TNF-a and IL-8 cytokines; however, the secretion kinetics and cumulative values showed significant differences. Although TNF-a production by M-MFs was moderate and reached maximum levels at an early time point (6 h), TNF-a secretion by GM-MFs was more robust and prolonged because it resulted in significantly higher concentrations at later time points (12-24 h) (Fig. 1A) . After LPS treatment, the production of IL-8 was similar in both MFs at the early time points (2-6 h); at later time-points, however, cytokine production by the GM-MF was 2-3-fold more intense. Nevertheless, MFs showed a substantial difference in terms of IL-6 and IL-10 production. Although LPS treatment induced a high amount of IL-6 production by GM-MFs, that cytokine was secreted in concentrations that were magnitudes lower than that produced by the M-MFs. However, in the case of the IL-10 anti-inflammatory cytokine, we observed the opposite, in which LPS treatment of M-MFs induced continuously increasing IL-10 cytokine production for up to 12 h, whereas the production of IL-10 by GM-MFs was below the detection limit.
Because IL-1b release by LPS-primed MFs requires a second stimulus, we collected medium from both ATP-treated and nontreated cells. We found that after ATP exposure, IL-1b production by GM-MFs was barely detectable at 2 h after LPS treatment; however, it gradually increased during the observed time interval (Fig. 1B) . Surprisingly, the LPS-primed M-MFs released high amounts of IL-1b at a very early time points because IL-1b was detectable from the supernatant as early as 30 min after LPS treatment (data not shown), reaching maximum production by 2 h. The amount of IL-1b thereafter decreased successively with time. Similar results were observed after nigericin treatment, indicating that the dynamics of LPS-primed NLRP3 inflammasome-induced IL-1b secretion fundamentally differs in the two MF types studied, and that difference was irrespective of the activating agent because ATP activates purinergic receptors, whereas nigericin induces pore formation.
As expected, we did not detect secreted IL-1b cytokine from the supernatant of LPS-treated M-MFs in the absence of ATP supplementation (Fig. 1C) . Surprisingly, however, LPS-activated GM-MFs secreted IL-1b in the absence of a second stimulus in comparable amounts to that produced by monocytes in similar conditions (Fig. 1C) .
Altogether, these results show that the same stimulating agent (LPS) used on 2 different human MF subtypes results in significant differences in the type and quantity of cytokine production. In addition, the results of cytokine production support the general notion that GM-MFs possess more proinflammatory properties than do M-MFs.
LPS-induced IL-1b production is mediated through the caspase-1-dependent NLRP3 inflammasome pathway in both MF subtypes Canonical IL-1b production requires the activity of caspase-1 as part of an inflammasome complex. To test the role of caspase-1 on IL-1b production in MFs, we used a caspase-1-specific inhibitor [16] and measured IL-1b production after LPS treatment ( Fig. 2A) . Our results show that the caspase-1-specific inhibitor Z-YVAD-FMK significantly reduced IL-1b production in both ATP-treated MF subtypes ( Fig. 2A) . Moreover, ELISA results demonstrated the necessity of the caspase-1 enzyme for IL-1b release by GM-MFs in the absence of ATP treatment. To further clarify the type of inflammasome involved in LPS-primed IL-1b production, we cultivated the cells in the presence of high KCl concentration, and observed a significantly suppressed IL-1b production (Fig. 2B) . Similar suppression was achieved by silencing NLRP3 using siRNA, without affecting IL-6 secretion (Fig. 2C) . These data together indicate that LPS-primed IL-1b production requires the caspase-1 enzyme and K + efflux and is mediated through the NLRP3 inflammasome complex in both M-and GM-MF subtypes.
Extracellular ATP released by GM-MFs does not directly affect NLRP3 inflammasome activation
Upon LPS stimulation, monocytes have been reported to release endogenous ATP, which triggers NLRP3 inflammasome activation and IL-1b release, whereas MFs are unable to process IL-1b upon LPS treatment because of the lack of ATP release [17] . When we measured the extracellular ATP content of the medium, we found a 4-fold higher ATP concentration in the medium of untreated GM-MFs compared with that of the M-MFs (Fig. 3A) . Interestingly, LPS treatment did not enhance the release of ATP by the cells; moreover, we observed a decline in ATP concentration in the medium of GM-MFs 24 h after LPS activation (Fig. 3A) . When we measured the expression of the ATP sensor P2X7R using quantitative real-time PCR and Western blot methods, we found that LPS treatment significantly induced the expression of the receptor in both cell types; however, we observed a faster decline of expression in M-MFs compared with GM-MFs (Fig. 3B) .
To test the functionality of P2X7R in the MFs and its contribution to IL-1b secretion, we used the P2X7R-specific inhibitor A740003 [18] . We found that the inhibitor abolished ATP-triggered IL-1b secretion by both LPS-primed MF types (Fig. 3C) . However, in the absence of ATP supplementation, the inhibitor failed to reduce IL-1b secretion by LPS-activated GM-MFs (Fig. 3D) . Similar results were obtained using apyrase enzyme that hydrolyzes extracellular ATP. We observed that, although the amount of extracellular ATP was significantly reduced in the presence of apyrase, the concentration of secreted IL-1b did not change significantly (Fig. 3D) .
These results altogether show that both MFs can express functional P2X7R, which is required for IL-1b secretion in cases of ATP supplementation. These data also show that LPSmediated IL-1b secretion in GM-MF is independent of released ATP.
CD39 and CD73 ectonucleotidases contribute to IL-1b secretion in GM-MFs
The net amount of extracellular ATP is the result of ATP released by cells and ATP hydrolyzed by ectonucleotidases. To assess the possible effect of ectonucleotidases on ATP concentration in the medium, we measured the gene transcription of CD39 (which hydrolyses ATP to ADP and AMP) and CD73 (which hydrolyses AMP to adenosine) from the two MF subtypes. We found that, although LPS treatment resulted in a 5-fold induction of CD39 transcription by 24 h in both MFs, the transcribed CD39 in GM-MFs was still significantly lower compared with that of the M-MFs (Fig. 4A) . In contrast, although the transcription of CD73 was temporarily increased in M-MFs, it was markedly elevated in GM-MFs 24 h after LPS activation.
To test the effect of ectonucleotidases on endogenous ATP catabolism and IL-1b release of GM-MFs, we treated the cells with the ectonucleotidase inhibitor ARL67156 [19] . We found that, in the presence of ARL67156, the ATP content was significantly elevated in the supernatant of both LPS-treated and nontreated cells (Fig. 4B) . Interestingly, however, when we measured IL-1b secretion of the GM-MFs, we detected a significantly decreased cytokine concentration in the ARL67156-treated cells, implying the possibility that, in GM-MFs, it is not the endogenous, released ATP but the accumulating side-or end-products of ATP hydrolysis that is required for IL-1b secretion.
Adenosine enhances IL-1b secretion in LPS-activated GM-MFs
The strongly elevated CD73 transcription in LPS-treated GM-MFs led us to assume that a significant amount of adenosine was produced as a by-product or an end-product. When we measured adenosine receptor transcription in the cells using quantitative real-time PCR (Fig. 5A) , we found that the A1 receptor was hardly detectable (data not shown). However, after a temporary increase, the expression of A2b and A3 was significantly inhibited and abolished by 24 h after LPS treatment, respectively, whereas the transcription of A2a was significantly induced and only moderately decreased in GM-MFs, in contrast to M-MFs in which the A2a receptor was dramatically decreased. At most time points, we detected greater transcription of A2a and A2b receptor expression in GM-MFs compared with M-MFs.
To test whether released endogenous adenosine contributes to LPS-mediated IL-1b secretion in GM-MFs, we treated the cells with adenosine receptor-specific antagonists [20] [21] [22] [23] (Fig. 5B) . We found that, in the presence of A2a-specific (ZM241385) and A2b-specific (PSB1115) antagonists, LPS-mediated IL-1b secretion was significantly decreased, whereas treatment with the A1-specific (DPCPX) and A3-specific (VUF5574) antagonists did not lead to significant changes in IL-1b secretion. To further support the notion that adenosine contributes to IL-1b secretion, we found that supplementing GM-MFs with an increasing amount of adenosine significantly enhanced LPS-mediated IL-1b secretion (Fig. 5B) . Similar results were obtained for GM-MFs in the presence of ATP supplementation because adenosine significantly increased LPS-primed IL-1b secretion. Interestingly, however, adenosine had no effect on IL-1b secretion in the LPSprimed M-MFs (Fig. 5C ). These results indicate that adenosine has an important regulatory effect observed only on the IL-1b secretion in GM-MFs independent of ATP supplementation, whereas it does not affect IL-1b secretion by M-MFs Differences in expression of NLRP3 and pro-IL-1b as well as in caspase-1 enzyme activity mediate diversity in IL-1b processing by GM-and M-MFs
To further investigate the molecular basis of the observed differences in IL-1b production by the MF subtypes, we first studied the activation of major signal transduction pathways (Fig. 6A) . In both M-MFs and GM-MFs, p38 and SAPK/JNK phosphorylation was detected as early as 10 min after LPS treatment. However, in GM-MFs, the intensity of the phosphorylation was only moderate during the studied time interval, whereas in M-MFs, we detected strong phosphorylation up to 60 min (p38) or 30 min (SAPK/JNK) after LPS activation. Furthermore, we found that ERK1/2 protein was already phosphorylated in the nontreated M-MFs, and the phosphorylation was further induced up to 30 min, declining thereafter by 60 min, whereas, in GM-MFs, there was clear induction at 10 min after LPS treatment, which increased by 30 min and was reduced at later time-points. Interestingly, although the LPS treatment resulted in strong phosphorylation of IkBa at an early time point (10 min) in the GM-MFs, in M-MFs, the activation of that pathway showed a shift to later time points, with robust phosphorylation only at 60 min. We also observed a decrease in the nonphosphorylated IkBa form in parallel with the appearance of the phosphorylated IkBa.
Next, we aimed to compare the expression of NLRP3 inflammasome components in the MFs after LPS treatment using Western blot methods (Fig. 6B) . We did not detect significant differences in the expression of the ASC adaptor and procaspase-1 because both untreated cell types expressed ASC and procaspase-1, and LPS treatment did not change the expression of these proteins. Nevertheless, we detected significant differences in the expression of the NLRP3 sensor molecule and . PCR results were obtained from 3 independent experiments with 3 replicates. Means 6 SD were *P , 0.05, **P , 0.01, ***P , 0.005 between control (0 h) and LPS treatment (2 h, 6 h, 12 h) or # P , 0.05, as indicated between LPS-treated M-MF and GM-MF (12 h, 24 h). From 3 independent experiments, 1 representative Western blot result is shown. (C) MFs were preincubated with A740003 (100 mM) for 1 h, followed by priming with LPS for 2 h (M-MFs) or 24 h (GM-MFs). Then supernatants were replaced with A740003 containing FCS-free medium supplemented with ATP. The amount of secreted IL-1b was determined by ELISA. Values correspond to 4 representative experiments means 6 SD (**P , 0,01, ***P , 0.001). N/D, not detectable. (D) In the absence of ATP, IL-1b secretion was quantified from supernatants of LPS-primed M-MFs (2 h) or GM-MFs (24 h) preincubated with A740003 (100 mM) or apyrase (2.5 U/ml) in the case of GM-MFs using ELISA method. Released ATP was detected from cell-free supernatant of GM-MFs. Data are expressed as means 6 SD of IL-1b (*P , 0.05), which was determined using ELISA.
pro-IL-1b. NLRP3 was clearly detectable in the nonactivated M-MFs, and 2 h after LPS activation, NLRP3 expression was at its peak, gradually decreasing by later time points. In contrast to M-MFs, although the expression of NLRP3 in untreated GM-MFs was hardly detectable, LPS treatment resulted in a continuously increasing NLRP3 protein expression. Pro-IL-1b, the inactive form of the cytokine, was not detectable in the nonactivated MFs. Although LPS treatment strongly and rapidly induced pro-IL-1b expression in both cell types, expression in M-MFs declined completely 24 h after LPS treatment, whereas, in GM-MFs, pro-IL-1b was continuously and strongly expressed during the 24 h time interval. The changes in NLRP3 and pro-IL-1b expression were also detected at the mRNA level as determined by the quantitative real-time PCR method (Fig. 6B) .
To detect the activation of NLRP3 inflammasome, the active forms of IL-1b and caspase-1 were determined. The presence of IL-1b in the cell lysate and in the medium of the cells was similar to that observed with ELISA. Upon LPS activation, in M-MFs, we detected an intensive caspase-1 band at an early time point (2 h) and moderate bands at 6 h, which were abolished by 12 and 24 h both from the cell lysates and the medium. For GM-MFs, the active forms of caspase-1 were weakly detectable; nonetheless, they showed an increase with time.
To better understand the function of caspase-1, we aimed to determine caspase-1 activity using a fluorogenic peptide substrate. We found that, in the absence of ATP, caspase-1 activity in M-MFs was hardly detectable, and LPS treatment did not have a significant effect on it (Fig. 6C) . Nevertheless, ATP treatment markedly affected enzyme activity in M-MFs because we detected significant caspase-1 activity, even in the absence of LPS treatment. Priming with LPS further increased the activity in the first hour; after which, it decreased gradually during the 24-h treatment. Surprisingly, in the absence of ATP, we detected significant enzyme activity in GM-MFs, even in the absence of LPS. In the presence of ATP, caspase-1 activity in the GM-MFs was moderately or significantly greater at each time point compared with activity in the absence of ATP.
Cumulatively, these results show that the substantially different expression and activity of the proteins by the two MF subtypes profoundly determine the outcome of LPS-induced IL-1b secretion.
Rapid attenuation of IL-1b secretion by M-MFs is the result of robust secretion of IL-10
The IL-10 cytokine has been known to be a negative regulator of many inflammatory responses. To investigate in-depth the rapid down-regulation of IL-1b secretion observed in M-MFs, we studied the possible effects of IL-10 on IL-1b cytokine production (Fig. 7A) . We found that secretion of IL-1b was significantly reduced after the administration of human recombinant IL-10 cytokine, which is in good agreement with the suppression of its transcription (Fig. 7A) . Furthermore, treating M-MFs with the anti-IL-10 mAb significantly increased IL-1b secretion and transcription by M-MFs (Fig. 7A) . IL-10 receptor ligation leads to an inhibition of the LPS-induced Akt signaling pathway. To study that mechanism, we compared Akt phosphorylation in the two MF subtypes after LPS stimulation by Western blot. Our results show (Fig. 7B) that Akt phosphorylation was significantly induced in GM-MFs at early time points after LPS stimulation, whereas, in M-MFs, that phosphorylation was weakly enhanced by the same stimulus (Fig. 7B) . When M-MFs were cotreated with LPS and recombinant human IL-10, we observed significantly reduced Akt phosphorylation compared with that induced by LPS alone, indicating that IL-10 affects this pathway in M-MFs (Fig. 7C) .
These results show that the rapid attenuation of IL-1b production by M-MFs is, in part, the result of the inhibitory effect of significantly induced IL-10 secretion, which attenuates Akt 
DISCUSSION
In the human system, M-CSF and GM-CSF are the most frequently used factors to differentiate blood monocyte-derived M-MFs or GM-MFs, respectively. Despite studies focusing mainly on general gene expression differences and some functions of those cells [13] , there are no comparative studies, to our knowledge, focusing on LPS-primed IL-1b secretion via NLRP3 inflammasome activation in these human MFs. When we compared LPS-induced cytokine secretion by these cells, we found that proinflammatory cytokine production was more pronounced in GM-MFs compared with that of M-MFs, whereas only M-MFs produced the IL-10 anti-inflammatory cytokine. These results are in line with the general notion that, in humans, GM-CSF treatment of monocytes results in the formation of MFs with a predominant role in proinflammatory responses. In contrast, M-CSF treatment leads to the generation of MFs that are more associated with wound healing and tissue repair functions [13, 24, 25] .
Our results showed that, in the presence of a second stimulus such as ATP or nigericin, both MF subtypes produced comparable amount of IL-1b, albeit with very different dynamics. The production of IL-1b and the activation of NLRP3 inflammasome are tightly regulated, and in MFs, require 2 signals. The first signal primes the cell, whereas the second signal, such as ATP, triggers the activation of the complex. In line with this, in the absence of a second stimulus, we did not detect IL-1b from the supernatant of the LPSmediated M-MFs; however, under similar conditions, we detected IL-1b production in the GM-MFs in amounts comparable to that produced by monocytes under the same conditions.
It was reported that LPS-activated human monocytes release nanomolar ATP, which acts in an autocrine or paracrine manner through P2X7R and induces IL-1b secretion [26] . In our studies, we found that both MF subtypes released nanomolar ATP, and it was significantly greater in the culturing medium of GM-MFs compared with that of the M-MFs. Nevertheless, unlike the case of TLR ligation in microglia and monocytes [27] , the concentration of released ATP did not increase upon LPS stimulation. We also observed that, although both MFs expressed comparable amounts of functional P2X7Rs, LPS-induced IL-1b production by GM-MFs was independent of the released endogenous ATP. Similar results were reported about GM-CSF-differentiated murine bone marrow-derived dendritic cells, showing substantial amounts of mature IL-1b production upon TLR activation, which was dependent on the NLRP3 inflammasome but independent of the P2X7R [28] . However, a definite molecular explanation has not been provided for the observed result. Based on our observations and on published reports, it seems that millimolar concentrations of ATP are needed for the activation of lowaffinity P2X7Rs for both M-MFs and GM-MFs [29] , which might be achieved locally and transiently during inflammation or cell injury in vivo [30, 31] . Indeed, ATP in the nanomolar range may induce signaling through high-affinity P2Y receptors and influence other cell functions, such as chemotaxis or rapid remodeling of the cytoskeleton for phagocytosis or migration [32, 33] . or with an increasing amount of adenosine (10 mM, 30 mM, 100 mM, 300 mM), followed by priming with LPS (24 h). IL-1b levels were determined from cell-free supernatants by ELISA. (C) MFs were preincubated with adenosine (100 mM) for 1 h; thereafter, cells were activated with LPS for 2 h (M-MFs) or for 24 h (GM-MFs). Before harvest, MFs were treated with ATP, and IL-1b secretions were analyzed from the cell-free supernatant. All ELISA data are expressed as means 6 SD of 3 independent experiments (*P , 0.1, **P , 0.01).
The actual amount of extracellular ATP was determined by the balance of ATP released from cells and ATP hydrolyzed by ectonucleotidases. Our results showed significant differences in the expression of both CD39 and CD73 after LPS treatment. Although it has been well documented that MFs express different ectonucleotidases to reduce inflammation by removing ATP and producing anti-inflammatory adenosine, the subtype of MFs as well as its polarization and activation determine the expression level of those enzymes. For example, expression of CD39 was reported to be up-regulated in peritoneal MFs and IL-4-treated bone marrow-derived MFs, which have immunosuppressive characteristics [34, 35] . Nevertheless, the increased enzyme activity of CD73 was described in human M-MFs treated with LPS + TNF, but was not induced in IL-4-treated cells [36] . The aforementioned findings, in addition to our own results, led us to speculate that the different expression of ectonucleotidases has an important, indirect regulatory effect on IL-1b production by GM-MFs. That notion was supported by our results showing a significant decrease in IL-1b secretion solely upon LPS activation in GM-MFs in the presence of ectonucleotidase inhibitor, whereas the extracellular ATP level was significantly increased. Following this conception, we speculated that inhibition of ectonucleotidase decreased the level of by-products and end-products of ATP hydrolysis, such as adenosine [37] .
Extracellular adenosine acts as a signaling mediator, participating in tissue regeneration, wound healing [38] , and immune responses, exerting mainly anti-inflammatory effects on dendritic cells, neutrophils, and MFs [39, 40] . Nevertheless, adenosine was also reported to induce IL-1b secretion because Figure 6 . Comparative analysis of signaling pathways, NLRP3 inflammasome members, and caspase-1 activation between LPS-activated M-MFs and GM-MFs. (A) MFs were primed with LPS, and the time-dependent phosphorylation of p-p38, p-ERK1/2, p-SAPK/JNK, and p-IkBa was detected from whole-cell lysates at the indicated time points by Western blot. Total p38, ERK1/2, SAPK/JNK, and IkBa were also detected using specific Abs, whereas b-actin amounts were probed to verify the same amount of protein loading. Western blots represented the part of M-MF and GM-MF that came from the same experimental blot. (B) MFs were primed with LPS for the indicated times, followed by treatment with ATP. The protein levels of NLRP3, ASC, procaspase-1, and pro-IL-1b were determined from the whole-cell lysates (Lys) (upper panel). The cleaved IL-1b (p17) and cleaved caspase-1 (p20) were quantified from precipitated supernatant (Sup) and whole-cell lysates (Lys) by Western blot. Western blots from supernatants or lysates are derived from the same samples but from different experimental blots. From 3 independent experiments, 1 representative Western blot result is shown. Transcription of pro-IL-1b and NLRP3 was determined by quantitative PCR (lower panel). Data are representative of 3 independent experiments. Gene expression is shown as the ratio of the studied transcripts relative to human cyclophilin expression (means 6 SD) measured in triplicates: pro-IL-1b **P , 0.005, ***P , 0.001; NLRP3 *P , 0.05, **P , 0.005. (C) Cell lysates were collected at the indicated time points after LPS or LPS plus ATP stimulation and were analyzed for caspase-1 activation using a fluorometric peptide substrate in triplicates. Values correspond to 3 representative experiments means 6 SD (*P , 0.1, **P , 0.01).
it regulates the duration of NLRP3 inflammasome activation through the A2a receptor. Those studies, however, involved murine peritoneal MFs, bone marrow-derived MFs [41, 42] , or the human THP-1 cell line [43] . Extracellular adenosine mediates its effects via activation of cell surface receptors (A1, A2a, A2b, A3). A2a and A2b receptors stimulate cAMP formation, and depending on the cell type, it may increase intracellular Ca 2+ levels, an important requirement for NLRP3 inflammasome activation [44] [45] [46] . Furthermore, it was reported that LPS treatment increases the extracellular level of adenosine in many cell types, including MFs [47, 48] . Indeed, our results show that, in the absence of ATP supplementation, adenosine treatment increased LPS-mediated IL-1b secretion by GM-MFs, and LPS-induced IL-1b production could be significantly inhibited by A2a-or A2b-specific receptor inhibitors. The stimulatory effect of adenosine on LPS-primed IL-1b secretion was also detectable under ATP supplementation in GM-MFs. Importantly, however, we did not detect a similar effect of adenosine in M-MFs, which contradicts the findings of Ouyang et al. [41] , who detected increased IL-1b secretion, although they used murine M-CSF-differentiated MFs. Considering the versatile, opposing, yet sometimes complementary effect of ATP and adenosine, changes in the balance of the ATP-adenosine axis and the local transient enrichment of any of these components may have a fine-tuning effect on the regulation of IL-1b secretion, depending on the cell type and the activating conditions. Nonetheless, further studies are needed to provide a detailed explanation on the cell-specific effects of these purinergic compounds.
We could not detect pro-IL-1b expression without LPS stimulation, indicating that LPS priming is essential for pro-IL-1b expression in both types of MFs. These results are in good agreement with current concepts suggesting that priming results in the de novo synthesis of pro-IL-1b and the up-regulation of NLRP3 [49] . However, from the striking differences in the dynamics of NLRP3 and pro-IL-1b expression between the two MFs, we speculated that different molecular mechanisms may determine the expression of these proteins in the two cell types. Multiple signaling pathways, including p38, JNK and ERK, have been reported as regulators of pro-IL-1b expression [50, 51] . Furthermore, activation of NF-kB and ERK phosphorylation were also reported as required regulators of NLRP3 expression [4, 6, 28, 52] .
We found, however, that LPS stimulation induced each of those studied pathways in both MFs with different dynamics, and, with the exception of NF-kB, the immediate activation was more pronounced in M-MFs. Importantly, we detected strong ERK phosphorylation in M-MFs, even in the unprimed cells, which is in line with reports showing that downstream signaling of M-CSF triggers activation of ERK pathway [53] . Because ERK signaling has been suggested as having a key regulatory role in the early events of priming [54] , we conclude that the constitutive background activation of ERK in M-MFs induced by M-CSF provides a "halfprimed" condition that results in continuous basal expression of NLRP3, which is normally provided by LPS in GM-MFs.
Our results showed strongly increasing IL-10 expression by M-MFs in parallel with the decrease of IL-1b as a complementary mechanism. IL-10, as an anti-inflammatory cytokine, may inhibit expression of several proinflammatory cytokines [55] [56] [57] . By inhibiting IL-10 binding to IL-10R, we demonstrated that the decrease observed in IL-1b production by M-MFs is, at least in part, mediated by IL-10. One of the most important signaling pathways affected by IL-10 is the Akt signal transduction cascades [58, 59] . Based on reports, IL-10 can abolish Akt phosphorylation, which, in turn, leads to decreased phosphorylation of downstream signaling pathways [60, 61] . We detected significantly weaker Akt phosphorylation in M-MFs compared with GM-MFs after LPS treatment, and in parallel, decreased phosphorylation of JNK and ERK 60 min after LPS stimuli. Considering that these pathways have an important regulatory role in the priming process of the NLRP3 inflammasome, the observed down-regulation of NLRP3, pro-IL-1b expression, and the following attenuation of IL-1b secretion in M-MFs may be explained, at least partly, by the indirect inhibitory effect of IL-10. However, proinflammatory cytokines, such as IL-6, are potent inducers of Akt phosphorylation and other cytokine production [62] [63] [64] . For that reason, the rapidly reduced expression of IL-1b in M-MFs could be a combined result of significant IL-10 production and the lack of proinflammatory cytokines such as IL-6.
We also found that, in addition to priming, the second signal, which can be provided by ATP, was necessary for activation of caspase-1 in M-MFs, because no caspase-1 activity was detected in the absence of ATP supplementation. However, under similar conditions, we detected constitutive caspase-1 activity in GM-MFs, which was further induced when cells were treated with ATP. There is an apparent contradiction between the detected caspase-1 activity and the absence of processed caspase-1 in the immunoblot. Processed caspase-1 is rapidly inactivated in cells [65] ; therefore, it is presumed that only a fraction of the immunologically detected caspase-1 has activity. Conversely, active caspase-1 may not necessarily be detected by immunoblot because the fluorescent assay is substantially more sensitive. Furthermore, the inactive caspase-1 fragments may be further modified for rapid proteasomal degradation [66] . The different mechanisms and dynamics of activation and inactivation/degradation of caspase-1 in the MF subtypes may also contribute to the observed results. The THP-1 monocyte cell line reportedly contains caspase-1 in a preactivated or primed state, even without an activating stimuli [67] . Furthermore, constitutive caspase-1 activation was reported in human monocytes purified from PBMCs. Similar to our observations, it has been shown that, because of the constitutively active caspase-1, a single stimulation such as LPS leads to the release of IL-1b in monocytes, whereas MFs require two distinct stimuli for cytokine release [17] . Notably, however, the MFs studied were generated either in the presence of 10% plasma or G-CSF. Nevertheless, because caspase-1 is an essential component of NLRP3 inflammasome-mediated IL-1b production, further studies are required to provide the molecular explanation for the constitutive activity of the caspase-1 enzyme.
In summary, we have shown here that several factors should be considered when conclusions are drawn using a particular in vitro system such as GM-CSF and M-CSF in human MF lineage biology. Although our knowledge about the general mechanisms of NLRP3 inflammasome function and its regulators is increasing rapidly, the actual outcome of IL-1b activation and production is strongly determined by the molecular characteristics of the cell type harboring various intracellular or extracellular modulators. For example, many studies have shown considerable differences between human and murine inflammasome activation [68, 69] . Our results may help clarify some controversial reports within the NLRP3 inflammasome field; the discrepancies of which are derived from methodological, cell type, and species differences in studies of NLRP3 inflammasome regulation. Our study sought to unravel the molecular mechanisms of LPS-primed NLRP3 inflammasome activation. Nevertheless, comparative analysis regarding other stimuli acting through different inflammasomes may also by important, and those studies still need to be conducted. Considering that GM-CSF and M-CSF are classic hematopoietic growth factors produced by various cell types upon versatile stimuli, as well as being therapeutic targets used in treatments, our results may aid in the development of potential therapeutic tools to better regulate IL-1b2mediated systemic or chronic diseases. 
